TP53 and cancer: Despite the notorious role of TP53 mutations in cancer, pharmacological intervention specifically targeting p53 mutations has been limited, with only a few targeted drugs, such as PRIMA-1 and PRIMA-1Met (APR-246), being tested in early clinical trials.